Because of its short-acting pharmacokinetic pro®le, remifentanil may be well suited for clinical situations in which a brief period of intense analgesia is desirable such as during painful diagnostic and therapeutic procedures performed outside the operating room. In such settings, practitioners may ®nd the gathering of the necessary equipment and the setting up of an infusion pump apparatus excessively inconvenient and therefore unappealing. If remifentanil could be safely and ef®caciously administered by bolus injection in such situations, practitioners may ®nd the ease and simplicity of the technique more appropriate for the out-of-operating-room setting.
To date, there is very little information describing the clinical pharmacology of remifentanil by bolus injection in awake subjects breathing room air. In fact, the current product labelling in the USA recommends bolus dosing of remifentanil only in patients who are undergoing general anaesthesia.
The primary aim of this observational study was to examine the safety of single bolus doses of remifentanil in conscious, healthy, adult volunteers breathing room air, particularly in terms of respiratory effects. Secondary aims included the evaluation of remifentanil pharmacokinetics and analgesic effects after bolus injection and a comparison of these aspects of remifentanil's clinical pharmacology in younger and older adults (over 60 yr). We hypothesized that remifentanil would be well tolerated in younger adults in bolus doses up to 200 mg and that older subjects would exhibit more substantial respiratory effects at all doses.
Methods and materials
After obtaining institutional approval and informed consent, potential volunteers were screened for study eligibility within 2 weeks of participation, with a target enrolment of approximately 60 subjects. The study was conducted as a randomized, double blind, two-period crossover, placebocontrolled, dose-escalation clinical trial.
Only English-speaking volunteers 18±59 yr (younger group) and 60 yr and over (older group) who were generally healthy (ASA I±II) were eligible for enrolment. All volunteers were required to be within 50% of their ideal body weight based on criteria described by Abernethy and Greenblatt. 3 Female volunteers were required to be nonlactating and to be either sterile (i.e. post-menopausal or surgically sterilized) or using an effective method of contraception. Potential subjects were excluded if they had a history of alcohol abuse or illegal drug use, a history of hypersensitivity to opioids, or a record of signi®cant psychiatric illness that might impair their capacity to give informed consent. Volunteers with renal or hepatic disease were also excluded, as were volunteers whose concurrent medications included drugs that are known to interact signi®cantly with opioids (including oral opioid analgesics).
Volunteers reported to the study site having abstained from tobacco products for 12 h, from solid food intake for 8 h and from clear¯uid intake for 4 h. Instrumentation included an 18 G i.v. catheter in an arm (with normal saline infusing at 100 ml h ±1 ) in all subjects and a 20 G radial artery catheter in subjects in whom blood samples for remifentanil concentration measurement were to be obtained (see below). Also, a nasal cannula was applied to each subject at the beginning of the experiment in preparation for the possible administration of oxygen after drug administration.
Safety monitoring included a ®nger pulse oximeter (Sp O 2 ), a three-lead continuous ECG and an automated arterial pressure cuff attached to the arm opposite the i.v. catheter. As a means of measuring ventilatory frequency, expired carbon dioxide was continuously measured (sampled through the nose).
In a randomized, double-blind, crossover manner, subjects received either remifentanil or placebo as the ®rst treatment in a ®xed unit dose (i.e. not weight adjusted) by bolus injection as rapidly as clinically feasible (i.e. 2±3 s). After a 1 h washout period, the second treatment was injected in a similar fashion, completing the crossover. Each dose was diluted in 8 ml of normal saline; each injection was immediately followed by a¯ush of normal saline (10 ml). Beginning with a unit dose of 25 mg, six subjects were studied at each dose level. The dose was increased in increments of 25 mg until a total of four out of six subjects in one dosage group experienced signi®cant respiratory depression (see below) or until a maximum dose of 200 mg was reached. Respiratory depression effects were measured using the respiratory intervention scale (RIS) as shown in Table 1 . In brief, the RIS is an observer assessment that quanti®es the degree of respiratory depression by incorporating the Sp O 2 and the subject's responsiveness into a graded score re¯ecting the degree of intervention necessary to normalize the subject's oxygenation status as assessed by pulse oximetry. The maximum RIS score was the primary endpoint for the measurement of respiratory depression (i.e. the RIS is a`one-time' measurement). Signi®cant respiratory depression was arbitrarily de®ned as a RIS score of 3 or more; once four of six subjects in a single dosage group reached a RIS score of 3 or more, the dosage escalation was stopped. The RIS methodology has been described in more detail elsewhere. 4 As the primary respiratory effect measure, the maximum RIS score during the ®rst 15 min after each injection was recorded. Episodes of apnoea and respiratory depression were also recorded as they occurred. Apnoea was de®ned as no breath for 15 s or longer and respiratory depression was de®ned as an Sp O 2 less than or equal to 85% for longer than 5 s or a ventilatory frequency of less than or equal to 8 bpm for 1 min or longer.
Pressure algometry was used to assess analgesic effect. In brief, the pressure algometer is a hydraulic device that is attached to the subject's middle to upper leg in a stable and comfortable position (the algometer is housed in two sheets of clear, thick plastic which are used to immobilize the leg). A painful stimulus is produced by applying the algometer's pressurized metal plunger (a¯at circular surface, 1 cm in diameter) to the skin at the anteromedial¯at surface of the tibia. Under the control of the investigator, the plunger pressure is incrementally increased (approximately 2 psi per s) up to a maximum pressure of 60 psi, which was arbitrarily de®ned as the maximal noxious stimulus. For each measurement, the subject was instructed to`say stop when you cannot tolerate the pain any longer'. Subjects were educated on the use of pressure algometry and were allowed to practice several algometry measurements before beginning the experiment. The pressure algometry methodology employed has been described in more detail elsewhere. 5 Pressure algometry measurements were made at 1, 3, 5 and 7 min after each treatment (injection) and then every 2 min until two consecutive measurements were within 15% of baseline. The onset of analgesia was de®ned as the time to achieve a pressure algometry measurement greater than 15% above baseline. The duration of analgesia was de®ned as the interval during which the pressure algometry measurement was greater than 15% above baseline.
Safety and drug effect measurements were made at preset intervals, with initial baseline measurements being made 15 min before the ®rst treatment. The Sp O 2 , ventilatory frequency, heart rate and systolic, diastolic and mean arterial pressures were recorded every minute during the ®rst 15 min after drug administration and then every 15 min during the 45 min washout phase.
Other adverse events such as episodes of nausea, vomiting and muscle rigidity were recorded as they occurred. In order to capture these events, volunteers were instructed to report spontaneously any concerns or disturbing symptoms to the investigator; volunteers were asked How do you feel?' by the investigators 15 min after each injection.
The analgesic response (i.e. the maximal algometry pressure tolerated) and the respiratory depression responses (i.e. the maximal RIS score and the minimum Sp O 2 ), were compared between different doses within each subject group (i.e. older vs younger) using the Kruskal±Wallis test corrected for multiple comparisons. These effects were also compared between subject groups using the Mann±Whitney rank sum test. P<0.05 was considered signi®cant.
In subjects who received 75 mg or more, arterial blood samples of 3 ml were obtained at preset intervals with the most rapid sampling immediately after treatment injection (samples were obtained during both the placebo and remifentanil limbs to maintain blinding). Samples were collected into heparinized tubes at baseline and at 1, 2, 4, 6, 8, 10, 15, 20, 30, 45 and 60 min after injection of the study drug (both remifentanil and placebo). To prevent continued metabolism of remifentanil after sample collection, the drawn blood was immediately transferred into previously prepared glass tubes containing citric acid, and frozen at ±70°C until the time of assay.
Remifentanil blood concentrations were measured by a high-pressure liquid chromatography method employing ultraviolet detection. The assay was validated between 0.1 and 100 ng ml ±1 with an interassay coef®cient of variation of less than 15% for concentrations greater than 0.1 ng ml ±1 . The sample preparation and assay methodology are described in detail elsewhere. 6 The raw concentration vs time data were analysed using several techniques. First, as an exploratory manoeuvre, each individual subject's pharmacokinetic parameters were estimated using standard compartmental modelling techniques. Guided by the results of this preliminary analysis, a mixedeffects population model was constructed. Finally, to help bring clinical meaning to the pharmacokinetic analysis, computer simulations were performed using the mixedeffects population pharmacokinetic model. Because it had been previously demonstrated for the remifentanil dose range employed in this study, linear pharmacokinetics were assumed for the purposes of this analysis. 7 Using the`two-stage' approach implemented on WinNonlin (version 3.0, Pharsight Corporation, Mountain View, CA, USA), both two-and three-compartment mamillary models were ®tted to the raw concentration vs time data to estimate each individual's pharmacokinetic parameters. These biexponential and triexponential disposition equations were parameterized in terms of clearances and apparent distribution volumes. Initial parameter estiClinical pharmacology of remifentanil bolus injection mates were obtained from our previous work. 8 Because the magnitude of the errors between the measured concentrations (C m ) and the concentrations predicted (C p ) by the model were presumed to be proportional to the predicted concentration, a proportional (1/C p 2 ) variance model was used for each ®t.
Guided by the results of the individual compartmental analysis in terms of the number of compartments and the initial parameter estimates, a mixed-effects model was built using WinNonmix (version 2.0, Pharsight Corporation, Mountain View, CA, USA), a mixed-effects modelling program. Mixed-effects modelling simultaneously analyses an entire population's data and provides estimates of typical values for the parameters, along with an estimate of the parameter's interindividual variability within the population studied.
Interindividual error on each parameter was modelled using a log-normal error model:
where q individual is the true value in the individual, q typical is the population mean estimate and h individual is a random variable whose distribution is estimated by WinNonmix with a mean of 0 and a variance of w 2 . The estimates of w obtained with WinNonmix are similar to the coef®cient of variation (CV) often used in standard descriptive statistics. Residual intra-individual error was modelled assuming a constant coef®cient of variation. The two-compartment model was parameterized in terms of distribution volumes and clearances.
The performance of the population model constructed using WinNonmix was assessed in terms of the ability to predict the measured blood concentrations. This was accomplished by plotting the observed concentrations against the predicted concentrations and by plotting the weighted residuals (WRs) as computed by WinNonmix against the predicted concentrations. These plots were then examined for accuracy and bias.
Computer simulations using the mixed-effects model were performed to illustrate the clinical implications of the pharmacokinetic analysis. The simulations predict the effect-site concentrations that would result from two alternative remifentanil dosing regimens that might be applied in clinical situations requiring a brief period (15 min) of intense analgesia (i.e. a 100 mg bolus followed by a 50 mg bolus every 2.5 min, and a 100 mg bolus followed by a 25 mg bolus every 1.5 min). The simulations were designed to target effect-site concentrations that are associated with analgesia and spontaneous ventilation (3±6 ng ml ±1 ). 9 The rate constant characterizing the equilibration between the plasma and the effect site concentrations (k e0 ) used for these simulations was obtained from our previous work. 10 
Results
Sixty-four subjects were enrolled and completed the study, including 48 in the younger group and 16 in the older group. Subject characteristics are summarized in Table 2 . The number of subjects enrolled for each dosage level (including placebo) is summarized in Table 3 .
There was a clear pattern of gradually increasing respiratory depression as the dosage was increased, although younger subjects receiving 75 mg or less experienced minimal respiratory depression, as re¯ected in RIS scores typically of 1 or less. In general, the respiratory depression, manifested by decreased respiratory rate and Sp O 2 , was rapid in onset (minimum Sp O 2 observed within the ®rst 2±4 min after injection) and short lived, rapidly responding to prompting and/or oxygen administration as Younger  Placebo  48  0  0  2  25  6  0  0  1  50  6  1  0  1  75  6  1  0  2  100  6  1  0  4  125  6  2  0  4  150  6  2  1  4  175  6  2  0  3  200  6  3  0  4  Older  Placebo  16  0  0  1  25  6  1  0  2  50  6  2  0  3  75  4  4  4  4 speci®ed by the RIS. Even at the highest doses (100±200 mg) administered to younger subjects, the respiratory depression observed was mild and easily managed, with RIS scores typically between 0 and 3. Older subjects experienced more signi®cant respiratory depression at lower doses than did the younger groups, with an average RIS score of 4 in the 75 mg dose group of the older cohort (further dosage escalation was therefore not undertaken). In fact, all four of the older subjects who received 75 mg exhibited a RIS score of 4. However, as with the younger cohort, the respiratory depression observed in the older subjects was short lived and easily managed as speci®ed by the RIS.
A summary of RIS scores for both the younger and older cohorts is displayed in Table 4 . No subject in either group at any dose required more than administration of nasal canula oxygen (2 litre min ±1 ) and verbal prompting to breathe to restore oxygenation to satisfactory levels (i.e. no subject achieved a RIS score greater than 4).
For the older group, the analgesic response (compared with placebo) reached signi®cance at doses above 50 mg (P<0.05). The increase in RIS and decrease in Sp O 2 levels were also signi®cant at doses above 50 mg compared with placebo (P<0.05). For the younger group, the analgesic and respiratory depression responses (both RIS and Sp O 2 ) reached signi®cance at doses of 75 mg and above compared with placebo (P<0.05). Between groups, the older group showed signi®cant decreases in Sp O 2 and increasing RIS score at the 75 mg level compared with younger adults given the same dose (P=0.02 and P=0.01, respectively).
The most serious respiratory events were episodes of apnoea, occurring in four subjects (a 68-yr-old male receiving 75 mg, a 36-yr-old male receiving 150 mg, a 27-yr-old female receiving 75 mg and a 21-yr-old male receiving 200 mg). All of these apnoeic episodes occurred within the ®rst 5 min after injection and lasted for 1 min or less. An additional subject (a 26-yr-old male receiving 175 mg) experienced an episode of respiratory depression that lasted for 1 min. Although these events were obviously regarded as serious, they were easily managed.
There was a clear pattern of gradually increasing analgesia as the dose was increased, although subjects receiving 25 mg or less had algometry responses not signi®cantly different from placebo (P<0.05), particularly for the older group. As with the respiratory effects, the algometry effects were rapid in onset and short-lived, with the maximal effects typically occurring within 1±2 min and lasting on average about 8 min. A summary of the analgesic response (i.e. onset, duration, maximal and time to maximal) as measured by pressure algometry for selected Clinical pharmacology of remifentanil bolus injection doses is displayed in Table 5 . The maximum percent algometry increase for each dosage level is displayed in Figure 1 . With regard to non-respiratory adverse events, in general the subjects tolerated the study very well. Although some subjects exhibited minor changes in heart rate and arterial pressure, there were no episodes of bradycardia or hypotension that were judged to be clinically signi®cant. Similarly, no episodes of muscle rigidity, or nausea or vomiting were detected by the investigators or reported by the subjects.
The drug administration scheme applied in this protocol resulted in concentration vs time curves characteristic of bolus injections. The raw concentration vs time data are displayed in Figure 2 . The raw concentration vs time data were adequately described by a two-compartment model. The average`two-stage' parameter estimates were a central clearance of 4.3 (SD 1.4) litre min ±1 , an intercompartmental clearance of 3.5 (2.5) litre min ±1 , a central distribution volume of 9.1 (7.1) litre and a peripheral distribution volume of 13.4 (7.1) litre. These parameter values were used as initial estimates for the mixed-effects population analysis. The ®nal data set for mixed-effects population analysis consisted of 273 measured blood concentrations and 48 dosing records. The mixed-effects, two-compartment model parameter estimates were a central clearance of 4.1 litre min ±1 (CV 16.4%), an intercompartmental clearance of 1.5 litre min ±1 (CV 21.9%), a central distribution volume of 5.6 litre (CV 26.5%) and a peripheral distribution volume of 10.9 litre (CV 21.2%).
The mixed-effects model performance was typical of compartmental models based on bolus drug administration where the measured drug concentrations decrease below the assay sensitivity quickly (i.e. the model does not perform as well as those based on more`data rich' studies). The model tended to slightly`overpredict' in the ®rst 1±2 min after injection, with a tendency to slightly`underpredict' thereafter. This shortcoming could probably be addressed by the addition of a third compartment, but the`two-stage' analysis of individual subjects suggested that only two compartments were necessary. The plots of observed concentrations against predicted concentrations and WRs against predicted concentrations are displayed in Figure 3 .
Computer simulations
The results of the pharmacokinetic simulations are displayed in Figure 4 . The upper panel, a simulation of a 100 mg bolus followed by 50 mg every 2.5 min, results in effectsite concentrations ranging from approximately 3 to 5.5 ng ml ±1 within the dosage interval. The lower panel, a simulation of a 100 mg bolus followed by 25 mg every 1.5 min, results in effect-site concentrations ranging from just over 3 to just over 4 ng ml ±1 within the dosage interval. The more frequent dosing interval of course results in less uctuation and more closely approximates a steady-state infusion. 
Fig 2
The raw concentration vs time curves for subjects in whom arterial blood samples were collected (subjects who received 75 mg or more). Note that no data from the older cohort are included (i.e. older cohort dose escalation ended at 75 mg). 
Discussion
This study has investigated the pharmacokinetics and pharmacodynamics of bolus-dose remifentanil in a healthy adult volunteer population, with a special focus on respiratory safety. The primary ®nding of the study is that remifentanil by bolus injection in doses of up to 200 mg is typically well tolerated in young, healthy adult subjects breathing room air, producing manifestations of repiratory depression that can be managed with verbal prompting to breathe and the administration of supplemental oxygen by nasal canula. Other essential ®ndings of the study are that remifentanil by bolus injection produces substantially more signi®cant respiratory depression in older adults (age over 60 yr) and that bolus-dose remifentanil can produce substantial analgesic effects that are characteristically short-lived.
The use of bolus-dose remifentanil is not new. Several investigators have examined the pharmacodynamics of bolus-dose remifentanil in various clinical settings. For example, remifentanil by bolus injection has been shown to be effective in preventing an untoward haemodynamic response to laryngoscopy and tracheal intubation.
11±13
Bolus-dose remifentanil has been used successfully in combination with propofol for orotracheal intubation without muscle relaxants. 14 15 Remifentanil by intermittent bolus injection has also been used successfully as a means of controlling undesirable increases in heart rate and arterial pressure during craniotomy procedures. 16 We studied remifentanil's effects when given by ®xed dose bolus injection to adults breathing room air. The study was primarily aimed at assessing the potential safety of remifentanil injection for procedures that might take place in various locations outside the operating room where patients will be breathing spontaneously without an arti®cial airway. Overall, the study con®rmed that bolus doses of up to 200 mg are well tolerated by younger adults breathing room air, in terms of both respiratory and haemodynamic effects. Signi®cant respiratory depression is to be expected, but it can typically be managed with supplemental oxygen administered by nasal canula and prompting to breathe.
Examining the pharmacokinetic simulations is perhaps the best way to understand the study's clinical implications. As demonstrated by the simulations in Figure 4 , frequent small bolus doses of remifentanil can be expected to produce a concentration vs time curve in the site of action (i.e.`effect site') that is a reasonable approximation of a steady-state infusion. Additional clinical study and computer simulation investigation will be necessary to identify the optimal dosage regimen for various clinical applications. It is important to recognize that the current study did not examine the safety of repeated bolus doses of remifentanil, although the fact that remifentanil's pharmacokinetics are linear suggests that pharmacokinetic simulation is a valid and useful way of exploring the clinical implications of new dosage regimens. 7 Although not presented here, comparison of the pharmacokinetic simulations shown in Figure 4 with simulations using the remifentanil pharmacokinetic parameters published by Minto and colleagues 17 were substantially similar, suggesting that kinetic parameters for remifentanil estimated from bolus injection administration are not markedly different from those estimated from continuous infusion administration. This issue has been a concern for some i.v. anaesthetics such as propofol. 18 In order to safely use remifentanil by bolus injection in patients breathing room air, it is important to understand not only the magnitude of the expected respiratory effects but also the time course of these effects. Babenco and colleagues 19 studied the time course of respiratory depression induced by remifentanil (by bolus injection) using a carbon dioxide rebreathing technique in healthy volunteers. They observed peak respiratory depression at 2.5 min after injection with substantial recovery at 6 min and essentially complete recovery by 15 min after injection. Although we did not study the time course of remifentanil's respiratory effects in the same way because our respiratory depression end-point was a one-time maximal score (i.e. the RIS), in general our ®ndings are consistent with the more detailed Clinical pharmacology of remifentanil bolus injection observations of Babenco and colleagues; that is, the respiratory depression we observed was maximal in the ®rst few minutes after injection, substantially recovered within 6 min and essentially resolved within 15 min after injection.
Several nuances relating to the respiratory depression observed in this study deserve highlighting. For example, it is important to note that some of the subjects who experienced the most severe respiratory events in this study had received doses that were substantially less than the maximum dose studied. It is also very important to emphasize that the older subjects in this study clearly exhibited more pronounced respiratory depression than younger subjects. In older patients with certain comorbidities (e.g. coronary artery disease), the degree of respiratory depression we observed after bolus remifentanil injection would certainly be viewed as serious and clinically very signi®cant.
The limited literature addressing the hazards of bolusdose remifentanil in terms of respiratory depression is certainly a cause for concern. In studying the safety and ef®cacy of bolus-dose remifentanil (with an ongoing continuous infusion) for pain management in the immediate postoperative period, several investigators have observed a high incidence of potentially life-threatening respiratory events (e.g. apnoea).
20±22 Although perhaps not entirely relevant to most clinical settings because of the intermittent nature of the pain, similarly serious adverse respiratory events have been observed when bolus-dose remifentanil has been employed as an analgesic for the relief of labour pain. 23 24 Because the degree of respiratory depression subjects experienced was highly variable and was occasionally signi®cant even at relatively low remifentanil doses, careful monitoring of respiratory function would be critical in the clinical setting when using remifentanil by bolus injection. Although all episodes of respiratory depression observed in the 64 subjects enrolled in this study were successfully treated with verbal prompting to breathe and the supplementation of inspired oxygen by nasal cannula, skills in the recognition and treatment of inadequate respiration would be obligatory when using bolus-dose remifentanil. Appreciation of the substantial respiratory depression synergy between opioids and sedatives would also be essential. Because of these dangers, it would be prudent for clinicians to gain experience with the clinical pharmacology of remifentanil by infusion before considering the use of remifentanil by bolus injection.
